Eloxx Pharmaceuticals
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
PO Box 274, Arlington, Massachusetts, 02...Phone Number
(781) 577-5300Website
www.eloxxpharma.comRevenue
-Stock Symbol
ELOXIndustry
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, with research operations in Rehovot, Israel. The company develops RNA-modulating, ribosome-targeted therapies for rare and ultra-rare genetic diseases caused by premature stop codon mutations. Its lead candidate, exaluren, is being developed for Alport syndrome and other kidney diseases associated with nonsense mutations. Eloxx has also licensed a related compound to a global pharmaceutical partner for development in rare skin diseases.Explore more
Eloxx Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Eloxx Pharmaceuticals
Compare insights from companies similar to Eloxx Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Eloxx Pharmaceuticals Tech Stack
A closer look at the technologies used by Eloxx Pharmaceuticals
See more technologies
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eloxx Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, with research operations in Rehovot, Israel. The company develops RNA-modulating, ribosome-targeted therapies for rare and ultra-rare genetic diseases caused by premature stop codon mutations. Its lead candidate, exaluren, is being develop... Read More
